FMXIN002
Type I Severe Allergic Reactions (Anaphylaxis)
Key Facts
About Nasus Pharma
Nasus Pharma is a publicly traded Israeli biotech focused on developing intranasal formulations for emergency and acute care, with a mission to replace invasive injections. Its lead asset, FMXIN002 (intranasal epinephrine), has completed Phase I for anaphylaxis, while FMXIN007 (intranasal dexamethasone) targets immunotherapy-related adverse events. The company's strategy hinges on validating its proprietary nasal delivery platform to address significant unmet needs in allergy and oncology supportive care, aiming for improved usability, compliance, and accessibility. As an early-stage public entity with a ~$20M valuation, it faces the dual challenge of clinical execution and navigating a competitive landscape.
View full company profile